Advertisement

Topics

Pappas Ventures Company Profile

15:18 EST 15th December 2018 | BioPortfolio

Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures. Most recently, in December 2009, the firm co-founded Afferent Pharmaceuticals, a spinout from Roche that is developing first-in-class treatments for chronic pain. Pappas Ventures has more than $350 million in capital under management, and has guided the launch and/or development of more than 50 life sciences companies, including Cerexa (acquired by Forest Laboratories), Peninsula Pharmaceuticals (acquired by Johnson & Johnson), Syntonix (acquired by Biogen IDEC), NuVasive (IPO), and Arena Pharmaceuticals (IPO). For more information about Pappas Ventures, please visit www.pappasventures.com.


News Articles [342 Associated News Articles listed on BioPortfolio]

Ribometrix Launches with $30 Million to Develop RNA Structure-based Drugs

Ribometrix closed on a Series A financing worth $30 million. The round was led by M Ventures, with participation of new investors Amgen Ventures, Pappas Capital and Illumina Ventures.

VelosBio closes $58mm Series A round

Oncology start-up VelosBio Inc. raised $58mm through its Series A round. Arix Bioscience and Sofinnova Ventures co-led and were joined by Pappas Ventures, Chiesi Ventures, and returning backers Takeda...

Series A lands $30mm for Ribometrix

Ribometrix Inc. (small-molecule therapies targeting RNA) raised $30mm in its Series A financing led by M Ventures, which adds a board member and was joined by first-time backers Amgen Ventures, Pappas...

Startup Future Family rakes in $10M to expand subscription fertility service

Aspect Ventures led the $10 million Series A round. BBG Ventures, LaunchCapital, iNovia, RiverPark Ventures, Ulu Ventures, Day One Ventures and Portfolia participated.

Arix Bioscience appoints Arthur Pappas to its board

League raises fresh capital to grow employee health benefits platform

The Canadian startup secured C$62 million (or about $47.5 million) in a round led by TELUS Ventures. Wittington Ventures, OMERS, RBC Ventures, Real Ventures, Infinite Potential Group and BDC IT Ventu...

Evidation completes $15mm Series B round

Evidation Health Inc. (digital medicines) closed a $15mm Series B round from new backers B Capital Group (lead) and Pappas Ventures, which were joined by returning investors GE Ventures, AMV, and Fres...

Neurotherapeutics discovery start-up System1 closes $25mm Series A round

System1 Biosciences Inc. (neurological and psychiatric disorder drug discovery using phenotypic screening) completed a $25mm Series A round co-led by CRV and Pfizer Ventures (both add board members). ...

Drugs and Medications [6 Associated Drugs and Medications listed on BioPortfolio]

Avant ex [B4 Ventures LLC]

B4 Brands: Avant EX Instant Hand Sanitizer

Avant foaming hand sanitizer [B4 Ventures LLC]

B4 Brands: Avant Foaming Hand Sanitizer - Fragrance Free

Avant original instant hand sanitizer [B4 Ventures LLC]

B4 Brands: Avant Original Instant Hand Sanitizer

Aterra antibacterial hand wash [B4 Ventures LLC]

B4 Brands: Aterra Antibacterial Hand Soap

Avant original - fragrance free [B4 Ventures LLC]

B4 Brands: Avant Original - Fragrance Free Instant Hand Sanitizer

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Achieving the maximum by doing the minimum in the treatment of pilonidal sinus : where does evidence point?

The article by Pappas et al highlighted the results of the laser treatment of Pilonidal disease (PND)[1]. Although this treatment seems impressive t there are a few points which merit discussion. The...

Estimating and valuing the carbon release in scenarios of land-use and climate changes in a Brazilian coastal area.

Deforestation is a significant source of man-made carbon in the atmosphere, contributing to the greenhouse gas (GHG) effect. Although carbon releases are associated to the ecosystem functions of clima...

"Yes, we know!" (Over)confidence in general knowledge among Austrian entrepreneurs.

Overconfidence has been reported to be a common bias among entrepreneurs and might be one cause of the high failure rates observed for new ventures. In this study, we investigate the overconfidence bi...

The implication of CRISPR/Cas9 genome editing technology in combating human oncoviruses.

It is evidenced that 20% of all tumors in humans are caused by oncoviruses including Human Papilloma Viruses (HPV), Epstein-Barr Virus (EBV), Kaposi Sarcoma Virus (KSHV), Human Polyomaviruses (HPyV), ...

Detecting opinion spams through supervised boosting approach.

Product reviews are the individual's opinions, judgement or belief about a certain product or service provided by certain companies. Such reviews serve as guides for these companies to plan and monito...

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Evaluation of a Digital Microscope for Malaria

Light microscopy, which is based on century-old technology, remains a key indicator in drug efficacy testing performed in the context of clinical trials for monitoring existing antimalaria...

Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2)

Microscopy remains a key indicator in drug efficacy testing performed in the context of clinical trials for monitoring existing antimalarials or in the context of regulatory clinical trial...

Companies [563 Associated Companies listed on BioPortfolio]

Pappas Ventures

Founded in 1994, Pappas Ventures invests exclusively in the life sciences sector – biotechnology, biopharmaceuticals, drug delivery, medical devices and related ventures. Mos...

At Pappas Ventures

Pappas Ventures, our sole focus is investing in the life sciences – biotechnology, specialty pharmaceuticals, drug delivery, medical devices and related ventures. Our success, however, is not simply...

CoLucid Pharmaceuticals, Inc.

CoLucid was founded in 2005 by Pappas Ventures to advance innovative drug candidates with the potential to provide safe and effective treatment for CNS disorders. The companyâ€...

CardioDx, Inc.

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care t...

Afferent Pharmaceuticals

Afferent Pharmaceuticals is focused on developing first-in-class medicines to treat chronic pain by targeting P2X3 receptors in nerve fibers. Research shows that P2X3-containin...

More Information about "Pappas Ventures" on BioPortfolio

We have published hundreds of Pappas Ventures news stories on BioPortfolio along with dozens of Pappas Ventures Clinical Trials and PubMed Articles about Pappas Ventures for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pappas Ventures Companies in our database. You can also find out about relevant Pappas Ventures Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record